First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology | Scientific Reports
ESMO 2018: JAVELIN Renal 101: A Randomized, Phase 3 Study of Avelumab + Axitinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma
ASCO GU 2021: Efficacy and Safety of Avelumab plus Axitinib (A + Ax) Versus Sunitinib (S) in Elderly Patients with Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Asco-GU 2019 – Bristol's renal cancer lead looks to be short-lived | Evaluate
Safety and Efficacy Data: The JAVELIN Renal 101 Trial
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - Annals of Oncology
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
ASCO GU 2021: Efficacy and Safety of Avelumab plus Axitinib (A + Ax) Versus Sunitinib (S) in Elderly Patients with Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101
ASCO GU 2019: JAVELIN Renal 101: Outcomes for Avelumab + Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma (RCC)
![PDF] Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e664af226abec8594ac677be056e2d38fe37bc93/6-Figure1-1.png "PDF] Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma | Semantic Scholar")
PDF] Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma | Semantic Scholar
Studienübersicht der Kombinationstherapien in der Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms
ASCO 2021: Association Between Neutrophil-to-Eosinophil Ratio (NER) and Efficacy Outcomes in the JAVELIN Renal 101 Study
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Request PDF
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine
Emerging Combination Therapies in Renal-Cell Carcinoma: Applying the Lessons from Clinical Trials to Clinical Practice
PFS according to the JAVELIN Renal 101 Immuno and JAVELIN Renal 101... | Download Scientific Diagram
Fabio Schutz on Twitter: "JAEVILIN Renal 101 preliminary results presented by Dr. Motzer. Double the ORR with Avelumab+Axitinib, and improved PFS. Overall population and PDL1 positive poliarquia with similar benefit. OS still
Updates ASCO GU 2019 - mRCC
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101 - ESMO Open
Using duration of response data from the JAVELIN Renal 101 study to... | Download Scientific Diagram
Dr. Elias reviews Keynote 426 and JAVELIN Renal 101 clinical trials – UT Southwestern Internal Medicine Journal Watch
